APUS

Apimeds Pharmaceuticals US, Inc. Common Stock (APUS)

About Apimeds Pharmaceuticals US, Inc. Common Stock (APUS)

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.

Details

Daily high
$1.88
Daily low
$1.75
Price at open
$1.88
52 Week High
$59.70
52 Week Low
$1.51
Market cap
2.9M
Dividend yield
-
Volume
63,977
Avg. volume
59,314
P/E ratio
-.06

Apimeds Pharmaceuticals US, Inc. Common Stock News

Details

Daily high
$1.88
Daily low
$1.75
Price at open
$1.88
52 Week High
$59.70
52 Week Low
$1.51
Market cap
2.9M
Dividend yield
-
Volume
63,977
Avg. volume
59,314
P/E ratio
-.06